PT

Dados B3 › BPHA3 × HYPE3

BPHA3 × HYPE3

BPHA3

MASSA FALIDA DA BRASIL PHARMA SA
Saúde

15 restated figures

HYPE3

HYPERA S/A
Saúde

37 restated figures

Indicators

Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.

indicatorBPHA3HYPE3year
ROE-149.5%13.9%2016
ROIC-348.5%!14.0%2017
ROA966.4%!10.9%2018
Gross margin98.3%!71.6%2018
EBIT margin-302.4%!33.0%2018
Net margin10,996.5%!30.3%2018
Net debt/EBITDA19.79x2.75x2013
Current ratio0.06x!3.04x2018
Revenue growth (1y)-17.5%!6.4%2018
Revenue growth (5y CAGR)-68.9%!-2.6%2018
Piotroski F-Score5/9!5/92018

Point-in-time multiples

Priced at the first session on or after the day each filing became public — never the period close.

indicatorBPHA3HYPE3year
P/E0.15x11.30x2018 × 2025
P/B—1.08x2018 × 2025
EV/EBITDA—10.17x2018 × 2025
FCF yield-55.2%13.1%2018 × 2025

BPHA3 · HYPE3 · filter the whole market · methodology

Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 08:32 UTC. If this does not match /saude, you are reading a cached copy.

Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.

Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 08:32 UTC. If this does not match /saude, you are reading a cached copy.